Evaluation of the Efficacy of Darolutamide Triplet Therapy in Patients With Metastatic Hormone-sensitive Prostate Cancer

ConditionsMetastatic Hormone-sensitive Prostate Cancer Darolutamide (DARO) in Combination With Androgen-deprivation Therapy (ADT) and Docetaxel (DOC)

Trial statusNot yet recruiting

Trial phaseNot listed

Trial typeObservational

Biological sexMale

Age18+

SponsorNanfang Hospital, Southern Medical University

About this trial

The purpose of this study is to investigate the clinical efficacy and safety of darolutamide combined with androgen deprivation therapy (ADT) and different dose-intensity docetaxel chemotherapy in the treatment of patients with metastatic hormone-sensitive prostate cancer.

Eligibility criteria

Qualifiers

None

Disqualifiers

None

Trial design

Treatments tested in this trial

Dose of docetaxel

Treatment groups

No treatment groups listed

Locations

This trial has no locations

Sponsors and collaborators

Nanfang Hospital, Southern Medical University

Lead sponsor

Source ClinicalTrials.gov